CASC3 and glioblastoma: BTZ is approved for the treatment of multiple myeloma and mantle cell lymphoma (Stapnes et al., 2007) and has been explored in early phase clinical studies for GBM (Kubicek et al., 2009; Friday et al., 2012; Bota et al., 2013; Kong et al., 2018; Rahman et al., 2020).